NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

| More on:
A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.

Image source: The Motley Fool

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NIB Holdings Limited (ASX: NHF) shares have been outperforming this year and delivered very strong returns for shareholders.

Since the start of the year, the private health insurer's shares are up a sizeable 24%.

This compares very favourably to the benchmark ASX 200 index, which is up approximately 6.5% over the same period.

Can NIB shares keep rising?

Unfortunately, the team at Macquarie thinks that the run is coming to an end, particularly given that a new headwind is emerging for one of NIB's businesses.

That headwind is the Department of Health preparing to respond to an Issues Paper assessing the level of commissions paid to third party agents.

The Department of Health is looking at the Overseas Student Health Cover market and is testing three items. Of particular interest to Macquarie is a potential cap on payments to third-party agents for distributing insurance policies to students.

While Macquarie notes that commission caps could make larger university contracts more valuable to NIB, it suspects that it could pressure the business model for agents.

Commenting on this potential headwind, the broker said:

A ~12% commission cap could be an outcome (some arrangements are currently 30%-40%). While insurer margins could increase in the short term, sales driven businesses (not supported by ancillary offerings) could struggle. Notably, NHF relies on sales agents (particularly in India), which could be at risk, while being underweight university contracts. Additionally, as one of the few insurers offering a full product lifecycle, slower sales to Students would negatively impact NHF's higher-margin Workers' policyholders.

We estimate Students represented ~33% / ~20% of Revenue / UOP in NHF's IIHI division in FY24. This would equate to ~2.2% of Group UOP, before accounting for stranded costs and conversion into Workers policies.

Shares tipped to fall

The note reveals that Macquarie has reaffirmed its underperform rating and $5.55 price target on NIB's shares. Based on its current share price of $6.87, this implies potential downside of 19% for investors over the next 12 months.

And while a ~4% dividend yield is expected over the next 12 months, this only limits the total negative return to approximately 15%.

Commenting on its underperform rating, the broker said:

Underperform. With multiple sub-divisions now experiencing operational headwinds, we retain our cautious outlook.

In light of this, investors may want to keep their powder dry for the time being and wait for a better entry point or for its headwinds to clear and tailwinds to emerge.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

After soaring 40% in 2 weeks, this ASX All Ords healthcare stock has been downgraded

Here’s what analysts at Macquarie rate the stock as now.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Own NIB shares? Here are the key dates for 2026

NIB has released its corporate calendar, including dividend dates, for 2026.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

ASX healthcare stock debuts at a massive discount to its initial public offer price

Saluda Medical shares have had a difficult start to public life, trading well below the initial public offer price.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Healthcare Shares

Why CSL shares now look 'massively oversold'

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which junior biotech's shares are flying on positive trial news?

This company's shares have surged higher after positive clinical trial results for its stroke treatment drug.

Read more »

Excited elderly woman on a swing.
Healthcare Shares

Guess which ASX 300 healthcare share is lifting off on $25 million news

The ASX 300 healthcare share is grabbing investor interest on Thursday. Let’s see why.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Doomed takeover bid for Mayne Pharma to come to an end

The Mayne Pharma takeover saga appears to be finally drawing to an end, with shareholders bearing the pain of the…

Read more »